Furthermore, Yang et al. asserted that a high expression level of PRF1 provided an appropriate microenvironment for anti-CTLA-4 and anti-PD-1/PD-L1 therapy in type I and II ovarian cancer [39]. This evidence concerns the gene CTLA4 and ovarian cancer.